Ozempic Lawsuit April 2026, 3,546 Cases Pending, FDA Warning Letter Issued, Vision Loss Trial Date Set

The Ozempic lawsuit just hit a major milestone this week. The Ozempic GLP-1 MDL added 183 cases between March and April, increasing from 3,363 to 3,546 pending cases. That growth alone tells you everything about the momentum of this litigation — roughly 200 new cases every month, no signs of slowing down, and two separate federal court tracks now running simultaneously. Here is everything that has happened in the past few days and weeks, and what you need to know if you or someone you know took Ozempic.

Quick Case Snapshot

Field	Details
Defendants	Novo Nordisk (Ozempic, Wegovy, Rybelsus); Eli Lilly (Mounjaro, Trulicity)
Primary MDL	MDL No. 3094 — GLP-1 RAs Products Liability Litigation
Vision Loss MDL	MDL No. 3163 — GLP-1 RAs NAION Products Liability Litigation
Court	U.S. District Court, Eastern District of Pennsylvania
Presiding Judge	Hon. Karen Spencer Marston
Total Cases (MDL 3094)	3,546 as of April 2026
Total Cases (NAION MDL)	73 as of April 1, 2026
Science Day Scheduled	June 2, 2026 (NAION/vision loss MDL)
Settlements So Far	None — no global settlement announced
Key Claims	Failure to warn; gastroparesis; NAION vision loss; wrongful death
FDA Warning Letter	Issued March 5, 2026 to Novo Nordisk
New Jersey State Action	30+ plaintiffs seeking multicounty litigation for vision loss

The Most Important Update This Week — FDA Warning Letter to Novo Nordisk

This is the biggest development in recent weeks and could significantly reshape the litigation.

The FDA issued a warning letter on March 5 to Novo Nordisk after inspectors found the company had failed to properly report serious adverse events associated with Ozempic and Wegovy. According to the agency, Novo Nordisk failed to submit certain incidents — including deaths — within the required 15-day reporting period and improperly withheld reports the company deemed “not causally related” to the drugs. Federal regulators stated that manufacturers are not permitted to make that determination themselves. Inspectors also pointed out flawed internal procedures for monitoring and assessing postmarketing safety data.

Why does this matter for the lawsuits? Because plaintiffs in both MDLs are already alleging that Novo Nordisk knew about risks and failed to warn patients. The FDA’s stance on mandatory reporting could directly influence discovery — especially as plaintiff attorneys examine which adverse events the company received and how it managed those reports. A federal regulator confirming that a drug company withheld safety data is exactly the kind of evidence plaintiff lawyers want in front of a jury.

What Just Happened in the Gastroparesis Cases — A Critical New Rule

As of April 5, 2026, some gastroparesis lawsuits will now have to be dismissed because victims who suffered through gastroparesis may now be required to get a gastric emptying study and cannot rely on clinical observations alone.

This is a major procedural development. In plain terms: Judge Marston has signaled that simply reporting symptoms is not enough — plaintiffs suing over stomach paralysis must have objective medical testing to back up their diagnosis. This will likely knock out some weaker cases but will not affect those with documented hospital records and formal clinical studies confirming gastroparesis.

What Are the Two Active Federal MDLs — And How Are They Different?

Most people searching “Ozempic lawsuit” do not realize there are now two separate federal court tracks running at the same time.

Related article: Kroger Sued Again Over Misleading Meat Labels — “Humane-Washing” Lawsuit Filed in California

MDL No. 3094 — General GLP-1 Injuries (Gastroparesis, Ileus, Bowel Obstruction)

Plaintiffs in Ozempic lawsuits allege that drugmaker Novo Nordisk failed to warn them about the potential risks of taking the medication. Ozempic can cause severe gastrointestinal injuries including gastroparesis (stomach paralysis), bowel injury (ileus), necrotizing pancreatitis, pulmonary embolisms, deep vein thrombosis (DVT), and in some cases, death.

Judge Karen Marston is expected to move the litigation toward coordinated discovery and begin identifying representative cases — called bellwether trials — that could eventually be prepared for trial testing. Resolving scientific disputes over whether the drugs can cause long-term gastrointestinal damage will be a key issue guiding discovery and pretrial proceedings throughout 2026.

MDL No. 3163 — Vision Loss / NAION Cases

A separate new federal MDL docket was established to centralize lawsuits alleging that GLP-1 drugs including Ozempic, Wegovy, Rybelsus, Mounjaro, and others caused serious vision loss linked to non-arteritic anterior ischemic optic neuropathy (NAION). The U.S. Judicial Panel on Multidistrict Litigation approved the creation of MDL No. 3163 in December 2025. This docket runs parallel to the existing GLP-1 MDL for gastrointestinal harms. Federal filings indicate that vision loss claims are being consolidated before the same judge overseeing the general GLP-1 MDL in the Eastern District of Pennsylvania.

NAION, in plain English, is a condition where the blood supply to the optic nerve is cut off — often causing sudden, severe, and permanent vision loss in one or both eyes. New lawsuits are being filed alleging that Ozempic and Wegovy caused severe and permanent vision loss, including blindness. According to recent complaints, patients developed NAION after using the semaglutide-based medications without adequate warning to patients or prescribing physicians about the potential risk.

Science Day Scheduled for June 2 — Why It Matters

Judge Karen Spencer Marston has scheduled a Science Day for June 2, 2026, in the Ozempic and Wegovy MDL concerning vision loss. Attorneys representing plaintiffs will be presenting evidence that Ozempic and other semaglutide drugs may increase the risk of NAION and associated vision loss.

A Science Day is not a trial — it is a specialized hearing where both sides bring expert scientists and medical witnesses to educate the judge on the underlying medical science. Think of it as the judge doing homework before deciding which expert testimony can be admitted at trial. The outcome of Science Day will determine how strong a scientific foundation plaintiffs can build their cases on. It is an encouraging sign to see a Science Day already slated for these lawsuits — it can sometimes take much longer before one is held.

New Jersey State Court Is Heating Up Too

Federal MDLs are not the only battleground. Novo Nordisk may soon face a coordinated mass tort proceeding in New Jersey state court over claims that its blockbuster weight loss drugs Ozempic and Wegovy caused permanent vision loss. More than 30 plaintiffs have petitioned for multicounty litigation designation. The plaintiffs allege that the drugs caused them to develop NAION, a serious and irreversible condition.

Many plaintiffs’ lawyers now see more promise in the NAION claims. The gastroparesis cases are not anywhere near dead but they are facing headwinds — particularly around causation, preexisting conditions, and the challenges of proving long-term injury from a gastrointestinal disorder that is often multifactorial.

What Novo Nordisk Is Arguing — The Defense Position

Novo Nordisk is not staying silent. The company has mounted an aggressive legal defense.

Novo Nordisk argues that the benefits of taking Ozempic outweigh any risks associated with the drug and dismisses claims related to severe side effects such as gastroparesis, intestinal obstruction, and gallbladder issues.

The defense has also pushed courts to require objective medical testing — like the gastric emptying study ruling — to filter out cases lacking clinical documentation. And on vision loss, the court has indicated that issues such as general causation and preemption must be resolved before trials proceed. “Preemption” is a legal argument that because the FDA approved the drug’s labeling, state-law failure-to-warn claims are blocked — a powerful but contested shield that will be heavily litigated.

No Settlement Yet — What That Means for You

While there have not been any Ozempic settlement agreements yet in the litigation, this may change as the MDL progresses. Typically in mass tort cases, both sides await the results of at least one bellwether trial before settlement negotiations begin.

Bellwether trials — test cases picked to represent the broader pool of plaintiffs — have not yet been selected. That selection process is expected to happen later in 2026, meaning a global settlement is likely at least a year or more away. In the meantime, individual cases continue to be filed and the MDL case count continues to climb.

Legal analysts estimate potential settlement values ranging from $100,000 to over $2,000,000 per case depending on injury severity, documentation, and evidence of corporate knowledge.

Who Qualifies to File an Ozempic Lawsuit?

Based on the current litigation framework, you may qualify if all of these apply:

✅ You took Ozempic, Wegovy, Rybelsus, Mounjaro, or another GLP-1 drug

✅ You were diagnosed with gastroparesis (stomach paralysis), ileus, intestinal obstruction, or NAION (vision loss/blindness)

✅ Your diagnosis occurred after starting the drug and was not fully explained by a pre-existing condition

✅ You required hospitalization, emergency care, or surgery related to the condition

✅ For gastroparesis claims: you may now need a formal gastric emptying study to support your claim

Cases that may no longer qualify: Some lawsuits for gastroparesis will now have to be dismissed because victims may be required to get a gastric emptying study and cannot rely on clinical observations alone. If you only experienced temporary nausea without hospitalization or objective testing, your case may be difficult to pursue under the current evidentiary standards.

Timeline of Key Events — 2023 to Now

Date	Event
August 2023	First Ozempic lawsuits filed
February 2024	MDL No. 3094 established, Eastern District of Pennsylvania
December 2025	MDL No. 3163 (NAION/vision loss) approved by JPML
March 3, 2026	Judge appoints leadership team in vision loss MDL
March 5, 2026	FDA issues warning letter to Novo Nordisk for failure to report adverse events
April 1, 2026	3,363 → 3,546 cases in main GLP-1 MDL
April 5, 2026	Gastroparesis ruling: gastric emptying study may now be required
June 2, 2026	Science Day scheduled — vision loss MDL
TBD 2026–2027	Bellwether trial selection expected
TBD	First bellwether trial
TBD	Global settlement negotiations

Frequently Asked Questions

Q: What is the latest update on the Ozempic lawsuit today?

 As of this week, the MDL case count climbed from 3,363 to 3,546. The FDA issued a warning letter to Novo Nordisk for failing to report serious adverse events — including deaths — on time. A Science Day hearing is scheduled for June 2, 2026. And a new ruling may require some gastroparesis plaintiffs to produce gastric emptying study results to keep their cases alive.

Q: Has there been any Ozempic settlement payout?

 No. As of April 2026, no global Ozempic settlement has been announced. Individual cases have not settled publicly. Settlement negotiations typically begin in earnest after at least one bellwether trial, which has not yet been scheduled.

Q: What injuries qualify for the Ozempic lawsuit?

 The primary qualifying injuries are gastroparesis (stomach paralysis), ileus, intestinal obstruction, and NAION (sudden vision loss or blindness). Pancreatitis, pulmonary embolism, DVT, and wrongful death claims are also being pursued by some plaintiffs.

Q: What is NAION and why is it important to the Ozempic lawsuit?

 NAION stands for non-arteritic anterior ischemic optic neuropathy — a serious condition where blood flow to the optic nerve is disrupted, causing sudden, often permanent vision loss. It is now the focus of a separate federal MDL (No. 3163) and is considered by many attorneys to be the stronger legal track in 2026.

Q: What is a Science Day in the Ozempic lawsuit?

 A Science Day is a special court hearing where both sides present expert medical and scientific evidence to the presiding judge. It is not a trial — it is an educational proceeding that helps the judge determine what science is admissible when the case goes to trial. The Ozempic vision loss Science Day is set for June 2, 2026.

Q: Can I still file an Ozempic lawsuit in 2026?

 Yes. New cases are still being accepted. However, the gastroparesis evidentiary requirements have recently tightened. Speak with an attorney as soon as possible — statutes of limitations (deadlines to file) vary by state, and some windows may be closing.

Last Updated: April 18, 2026

This article is for informational and news reporting purposes only and does not constitute legal advice. Allegations in lawsuits are not findings of fact or liability. Consult a licensed attorney about your specific circumstances.